00:02 , Jun 26, 2019 |  BC Extra  |  Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

Conatus cuts headcount by 40% to extend runway  Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said it will lay off 40% of its staff and suspend development of caspase 1 inhibitor CTS-2090 in a bid to extend its...
20:47 , Jun 21, 2019 |  BC Extra  |  Clinical News

AnaptysBio shares sag as Sanofi-Regeneron trial stokes IL-33 doubts

A 12% dip in AnaptysBio's share price Friday suggests investors are concerned that a Phase II readout for a rival IL-33 inhibitor could indicate that the drug class may not provide a differentiated clinical benefit...
18:38 , Jun 2, 2019 |  BC Extra  |  Company News

Aslan’s change of course on eczema asset brings flexibility for future deals

Aslan's decision to restructure an existing deal with CSL for atopic dermatitis candidate ASLAN004, extending the partnership's scope to give the biotech full commercial rights, is part of Aslan's broader intention to gain flexibility for...
22:06 , May 7, 2019 |  BC Extra  |  Company News

May 7 Company Quick Takes: Akcea, Bicycle/DDF, Arbutus, Celgene/Sutro, MDGH, Pfizer, Sanofi/Regeneron

Akcea's Waylivra approved in EU  The European Commission granted conditional approval to Waylivra volanesorsen from Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) as an adjunct to diet in adult patients with familial chylomicronemia...
14:23 , Mar 20, 2019 |  BC Extra  |  Financial News

Follow-on roundup: Dermira, resTORbio, NanoString

Dermira raised $130 million in an upsized offering that followed closely after its eczema readout this week, while resTORbio and NanoString also priced follow-ons late Tuesday. Dermira Inc. (NASDAQ:DERM) sold 9.8 million shares at $13.25,...
17:37 , Mar 18, 2019 |  BC Extra  |  Clinical News

Dermira jumps on Phase IIb atopic dermatitis readout

Dermira added $5.77 (84%) to $12.61 on Monday after reporting that all three doses of lebrikizumab met the primary endpoint in a Phase IIb trial to treat adults with moderate-to-severe atopic dermatitis. Dermira Inc. (NASDAQ:DERM)...
22:32 , Mar 11, 2019 |  BC Extra  |  Company News

FDA approves Dupixent for atopic dermatitis in adolescents

FDA on Monday approved the first biologic for adolescents with moderate-to-severe atopic dermatitis, Dupixent dupilumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY). The partners already market the human mAb targeting the α...
17:36 , Mar 8, 2019 |  BC Week In Review  |  Company News

CHMP recommendations include Ondexxya, Waylivra

EMA's CHMP recommended a basket of approvals and label extensions on March 1, including Ondexxya andexanet alfa and Waylivra volanesorsen. The agency recommended conditional approval of Ondexxya from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) as the first...
22:10 , Mar 1, 2019 |  BC Extra  |  Company News

CHMP recommendations include Ondexxya, Waylivra

EMA's CHMP recommended a basket of approvals and label extensions Friday, including Ondexxya andexanet alfa and Waylivra volanesorsen. The agency recommended conditional approval of Ondexxya from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) as the first approved antidote...
19:32 , Mar 1, 2019 |  BC Week In Review  |  Clinical News

Phase III nasal polyps data for Dupixent presented at AAAAI

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) presented detailed data at the American Academy of Allergy, Asthma & Immunology meeting from a pair of Phase III trials evaluating Dupixent dupilumab to treat recurring...